Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

  • STATUS
    Recruiting
  • End date
    Jun 30, 2027
  • participants needed
    1616
  • sponsor
    Shanghai MicroPort Medical (Group) Co., Ltd.
Send
Updated on 4 October 2022
See if I qualify
stenosis
sirolimus
everolimus
heart disease
unstable angina
troponin
ischemia
exercise stress test
biodegradable polymer
coronary disease
zotarolimus

Summary

The aim of the TARGET-IV NA trial is to demonstrate the clinical non-inferiority of the Firehawk rapamycin eluting stent system in comparison to currently approved 2nd generation DES for the treatment of subjects with ischemic heart disease (NSTEMI, recent STEMI (>24 hours from initial presentation and in whom enzyme levels have peaked), unstable angina, and stable coronary disease), with atherosclerotic target lesion(s) in coronary arteries with visually estimated reference vessel diameters 2.25 mm and 4.0 mm.

Description

TARGET-IV NA trial is a prospective, multicenter, 1:1 randomized (Firehawk vs. 2nd generation DES), trial.

Sub studies:

Angiographic sub study: The first approximately 200 consecutive consenting patients will be enrolled in the angiographic substudy. Optical coherence tomography (OCT) substudy: The first approximately 50 consecutive consenting subjects will be enrolled in the OCT substudy.

Clinical follow-up will be performed at 30 days, 6 months, and 1, 2, 3, 4, and 5 years post randomization. First approximately 200 consecutive consenting patients will undergo planned angiographic follow-up at 13 months after enrollment, with first 50 of these patients also consented to undergo planned OCT at baseline and at 13 months following randomization.

Details
Condition Cardiac Ischemia, Myocardial Ischemia, Coronary heart disease, Coronary Artery Disease
Treatment Microport Firehawk stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Clinical Study IdentifierNCT04562532
SponsorShanghai MicroPort Medical (Group) Co., Ltd.
Last Modified on4 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Age 18 years
Patient (or legal guardian) understands the trial requirements and treatment procedures and provides written informed consent prior to any trial-specific tests or treatment
Patients with an indication for PCI including angina (stable or unstable), silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of 70%, a positive non-invasive stress test, or a positive coronary physiology test (e.g. FFR0.80 or iFR<0.90 or rFR 0.89 must be present), NSTEMI, or recent STEMI (STEMI >24 hours and in whom enzyme levels have peaked). For STEMI the time of presentation to the first treating hospital, whether a transfer facility or the study hospital, must be >24 hours prior to randomization and enzyme levels (CK-MB or Troponin) demonstrating that either or both enzyme levels have peaked
Patient is willing to comply with all protocol-required follow-up evaluations
Angiographic inclusion criteria
Target lesion(s) must be located in a native coronary artery with visually estimated diameter of 2.25 mm to 4.0 mm and up to 44 mm in length
The coronary anatomy is deemed likely to allow delivery of a study device to the target lesion(s)
Complex lesions are allowed including calcified lesions (lesion preparation is allowed and strongly recommended with current approved devices (e.g. scoring/cutting balloon and rotational/orbital atherectomy), multivessel disease, CTO,bifurcation lesions (except planned dual stent implantation), ostial lesions, tortuous lesions, and protected left main lesions
Overlapping stents are allowed

Exclusion Criteria

STEMI within 24 hours of initial time of presentation to the first treating hospital, whether at a transfer facility or the study hospital or in whom enzyme levels (either CK-MB or Troponin) have not peaked
PCI within the 24 hours preceding the baseline procedure
History of stent thrombosis
Cardiogenic shock (defined as persistent hypotension (systolic blood pressure <90 mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support, including IABP
Subject is intubated
Known LVEF <30%
Subject has a known allergy to contrast (that cannot be adequately pre-medicated) and/or the trial stent system or any protocol-required concomitant medications or devices (e.g. cobalt chromium alloy, stainless steel, sirolimus, everolimus or structurally related compounds, polymer, any P2Y12 inhibitor, or aspirin)
Planned surgery within 6 months
Subject has an indication for chronic oral anticoagulant treatment (with either vitamin K antagonists or novel anticoagulants - NOACs)
Calculated creatinine clearance <30 mL/min using Cockcroft-Gault equation (<40 mL/min for subjects participating in the angiographic follow-up sub-study)
Hemoglobin <10 g/dL
Platelet count <100,000 cells/mm3 or >700,000 cells/mm3
White blood cell (WBC) count <3,000 cells/mm3
Clinically significant liver disease
Active peptic ulcer or active bleeding from any site
Other serious medical illness with a life-expectancy < 24 months (e.g. cancer, severe heart failure, severe lung disease)
A planned procedure that may cause non-compliance with the protocol or confound data interpretation
Participation in another investigational drug or device trial that has not yet reached its primary endpoint and that may interfere with protocol compliance or confound data interpretation (as per the opinion of the investigator); or intent to participate in another investigational drug or device trial within 12 months
Intention to become pregnant within 12 months (women of child-bearing potential who are sexually active must agree to use contraceptives from the time of enrollment through 12 months post-procedure)
Pregnancy or nursing (women of child-bearing potential must have a pregnancy test within 7 days prior to the index procedure)
Any co-morbid condition that may cause non-compliance with the protocol (e.g. dementia, substance abuse, etc.)
Subject has received an organ transplant or is on a waiting list for an organ transplant
Subject is receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease (e.g., HIV). Corticosteroids are allowed
Angiographic Exclusion Criteria
Unprotected left main interventions
Bifurcation lesions with intended dual stent implantations
DES restenotic lesions
Prior PCI in the target vessel in the 12 months prior to enrollment
Any lesion in the target vessel that is likely to require PCI within 12 months
Stent lengths >36mm for diameters 2.0 mm and 2.25 mm (i.e., very long thin stents)
Lesion with intended 3 stent implantation
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

stenosis
sirolimus
everolimus
heart disease
unstable angina
troponin
ischemia
exercise stress test
biodegradable polymer
coronary disease
zotarolimus

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note